pharmaphorum

DECEMBER 24, 2020

The US National Institutes of Health said that the research it had co-funded used AI to transform a bacterial protein into a new research tool. In the study, researchers transformed a nutrient-grabbing Venus-flytrap shaped bacterial protein into a highly sensitive fluorescent sensor that lights up when it captures serotonin.

Development 67

Development Drugs Protein Genetic Engineering 67

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells.

Development 77

Development Drugs Manufacturing Immune Response 77

Drug Discovery World

NOVEMBER 27, 2023

Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow. This article is sponsored by Revvity.

Production 59

Production Engineer Gene Editing Gene 59

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

XTalks

MARCH 18, 2024

The precision fermentation study highlights how genetically engineered microorganisms can inhibit the growth of foodborne pathogens. Words like “bioengineered” and “genetically modified” often provoke negative reactions. This not only extends the shelf life of foods but also ensures they are safer for consumption.

Genetic Engineering 52

Genetic Engineering Genetics Production Protein 52

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Drug Discovery World

MAY 7, 2024

However, despite these advancements in process optimisation and cell culture engineering, there remain areas that we need to improve. RA: What are some of the current limitations for producing mAbs? DC: For the past few decades, there have been many advancements in the biotechnology space.

Antibody 59

Antibody Production Manufacturing Engineer 59

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

XTalks

SEPTEMBER 15, 2022

Food products which are developed using genetically modified organisms (GMOs) are possible through bioengineering and precision fermentation is powered by biotech. Some companies are using precision fermentation to create things like dairy and egg protein without animals. Biotechnology is also taking on new forms in food.

FDA Approval 95

FDA Approval Genetic Engineering Genetics Production 95

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. For example, if a patient’s tumour has a particular protein present, called a checkpoint protein, this will reduce the response of T-cells.

Research 98

Research Protein Scientist Immune Response 98

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 mutations, as well as variants from the UK and South Africa.

Vaccination 60

Vaccination Vaccine Genetic Engineering Engineer 60

pharmaphorum

NOVEMBER 6, 2020

Novartis is also working with Molecular Partners to develop therapies based on genetically engineered proteins known as DARPins. These are small proteins that are created in the lab but mimic the effect of antibodies and could be used to neutralise the SARS-CoV-2 coronavirus that causes COVID-19.

Trials 40

Trials Genetic Engineering Licensing Licensing 40

Drug Discovery World

NOVEMBER 17, 2022

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. However, the development of drugs takes decades which is too long for most biotech start- ups looking for fast-track drug development programs.

Bacteria 52

Bacteria Engineer Gene Genetics 52

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 23, 2020

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

MARCH 6, 2024

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. On the other, the development of smaller, portable MRI machines is favored for their ease and convenience. The neurodegenerative disease market alone, valued at $51.2

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

XTalks

MARCH 28, 2024

Colorectal Cancer: Advances in Treatment Options In recent years, there has been considerable progress in understanding the biology of CRC, which has helped develop more effective and personalized treatment options. An overview of some of the most promising developments in CRC treatment is provided below.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

The Pharma Data

JUNE 1, 2022

Scientists who have long studied this molecule’s functions in bacterial infections traced development of extensive lung damage in infected mice to heightened levels of the enzyme triggered by the invading SARS-CoV-2 virus. They used a version of the SARS-CoV-2 virus that other scientists have engineered specifically to cause disease in mice.

Immune Response 52

Immune Response Genetic Engineering Engineer Research 52

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Using complex models of cancer for preclinical testing After a coffee break, Prof Sansom was back behind the podium talking about the MRC National Mouse Genetics Network.

Research 52

Research Drugs In-Vitro Insulin 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , About Aridis Pharmaceuticals, Inc.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

JULY 27, 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

Pharmaceutical Technology

SEPTEMBER 5, 2022

CNBC reported in April last year that the vaccine is being developed by the company in partnership with the Beijing Institute of Biotechnology (BIB). Administered as a single dose, the genetically engineered vaccine has the replication-defective adenovirus type 5 vector that expresses the spike S protein of the SARS-CoV-2 virus.

Vaccination 264

Vaccination Vaccine Genetic Engineering Clinical Trials 264

Pharmaceutical Technology

JUNE 4, 2023

There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Transcription of the rep gene is initiated from the p5 or p19 promoters to, respectively, produce the large (Rep78 and Rep68) and small (Rep52 and Rep40) nonstructural Rep proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

Drug Discovery World

JULY 22, 2022

Compared to controls, CAR-T cells engineered to target HER2 expressing melanoma cells significantly reduced tumour volumes in hIL2 immunodeficient mice. hIL15 immunodeficient mice are emerging as potential models for investigating these therapies based on IL15’s involvement with NK cell development 18. Forsberget al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Gene splicing using nucleases is used to design gene therapeutics for various genetic disorders.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Roots Analysis

AUGUST 31, 2023

Further, the expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. There are various regulatory proteins or transcription factors that are responsible for affecting the transcription rate. When activator binds to the operon, it either speeds up or permits gene expression.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Roots Analysis

FEBRUARY 15, 2022

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. The TAL protein consists of 33-34 amino acid repeat patterns, with two variable positions.

Genome 52

Genome Genomics Gene Editing DNA 52